Hamilton, Canada
Insight Medbotics is an innovative player in the Biopharma, Biotechnology, and Health Care sectors. Founded in 2017 and headquartered in Canada, the company is at the forefront of developing MRI-guided robotics technology, aiming to merge the diagnostic insights of MRI with the precision and minimally invasive capabilities of robotics.
Their flagship product, the MRI-compatible robot IGAR, has achieved significant milestones, including receiving an FDA 510(k) clearance, making Insight Medbotics the sole entity authorized to use a robot within an MRI. This regulatory achievement facilitates their focus on enhancing prostate cancer treatment, with future plans to extend this precision technology to other critical surgical procedures.
The company received a Seed Round investment of $435.00K in April 2022 from the McMaster Seed Fund (MSF), underscoring investor confidence in their potential to revolutionize healthcare delivery. With their commitment to "When accuracy and precision matter most," Insight Medbotics positions itself as a compelling candidate for investment aimed at transforming modern medical care.
